Aquestive Therapeutics (US.AQST)
Capital Allocation Audit · Period: 2016 – 2026
Key Metrics
US.AQST · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.4% | → |
| ROE | - | → |
| Cash Conversion | - | → |
| D/E Ratio | - | → |
| Gross Margin | 76.0% | ↑ |
US.AQST (Aquestive Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.4% → ROE - → Cash Conversion - → D/E Ratio - → Gross Margin 76.0% ↑
Key Metrics
US.AQST (Aquestive Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.4% →ROE - →Cash Conversion - →D/E Ratio - →Gross Margin 76.0% ↑Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies